[Treatment of uveitis-associated refractory ocular hypotony with topical ibopamine].

Abstract

BACKGROUND:

Ibopamine is a non-selective dopamine- and adrenalin-receptor agonist that has been shown to cause pupillary dilation and an increase in aqueous humour secretion. This novel drug can be used as a mydriatic agent, as a provocative test in open-angle glaucoma, and for the treatment of persisting ocular hypotony.

HISTORY AND SIGNS:

This 47-year-old man had a history of uveitis associated with Crohn's disease. Six years after deep sclerectomy for uveitic secondary glaucoma, he developed severe hypotony in his left eye with drop of visual acuity (VA). The hypotony did not respond to topical steroid treatment. 2 % Ibopamine solution was ordered t. i. d. concomitant to 1 % prednisolone acetate.

THERAPY AND OUTCOME:

Intraocular pressure (IOP) began to rise after 3 weeks of Ibopamine treatment and returned to normal (12 mmHg) with continuous recovery of VA after 8 weeks. Ibopamine was discontinued at an IOP of 16 mmHg after a course of 12 weeks. IOP and VA remained stable during the 12-month follow-up period.

CONCLUSIONS:

Ibopamine 2 % eye drops in combination with topical steroids are a therapeutic option in uveitis-associated ocular hypotony.

• Authors: B K Windisch, M E Iliev
• Journal: Klinische Monatsblatter fur Augenheilkunde (Klin Monbl Augenheilkd) Vol. 223 Issue 5 Pg. 422-4 (May 2006) ISSN: 0023-2165 [Print] Germany
• Vernacular Title: Therapie einer refraktären okulären Hypotonie bei Uveitis mit topischem Ibopamin.
• PMID: 16705521 (Publication Type: Case Reports, English Abstract, Journal Article)

Chemical References

• Mydriatics
• ibopamine
• Deoxyepinephrine

Topics

• Administration, Topical
• Chronic Disease
• Deoxyepinephrine (administration & dosage, analogs & derivatives)
• Humans
• Male
• Mydriatics (administration & dosage)
• Ocular Hypotension (etiology, prevention & control)
• Treatment Outcome
• Uveitis (complications, drug therapy)